Kailera Therapeutics Inc.

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
Kailera Therapeutics Inc.
Ownership
Public
Status
Active
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Delaware
Headquarters city
Waltham
Headquarters state / province
Massachusetts
Headquarters country
United States
Fiscal year end
December
Ticker symbol
KLRA
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0002096997

Board of directors

Follow this board

Chief executives

Ronald C. Renaud Jr. · CEO & President
Since April 2026

Board connections

7 of this board's directors also sit on 11 other boards.

Network of Kailera Therapeutics Inc.'s board connections 4D Molecular Therapeutics Inc. 4D Molecular Therapeut... Cencora Inc. Cencora Inc. Charles River Laboratories International Inc. Charles River Laborato... Foghorn Therapeutics Inc. Foghorn Therapeutics I... Pacific Biosciences of California Inc. Pacific Biosciences of... Rallybio Corporation Rallybio Corporation Revolution Medicines Inc. Revolution Medicines I... Solid Biosciences Inc. Solid Biosciences Inc. Surgery Partners Inc. Surgery Partners Inc. Upstream Bio Inc. Upstream Bio Inc. Vera Therapeutics Inc. Vera Therapeutics Inc. Adam Koppel Adam Koppel Andrew T. Kaplan Andrew T. Kaplan Christopher Hite Christopher Hite Frank Clyburn Frank Clyburn John F. Milligan John F. Milligan Martin Mackay Martin Mackay Ronald C. Renaud Jr. Ronald C. Renaud Jr. Kailera Therapeutics Inc.
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$326,750,016
5 purchases by 5 insiders
Sold, last 12 months
$0
0 sales by 0 insiders
Date Insider Transaction Shares Price Value
Jun 9, 2026 Ronald C. Renaud Jr. Director, Officer (CEO & President) Option exercise +38,094 $5.25 $199,994
Apr 20, 2026 RTW INVESTMENTS, LP 10% owner Derivative conversion +10,276,820 — —
Apr 20, 2026 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner Derivative conversion +9,477,719 — —
Apr 20, 2026 BCPE Perseus Investor, LP 10% owner Derivative conversion +17,857,143 — —
Apr 20, 2026 Adam Koppel Director, 10% owner Derivative conversion +16,875,000 — —
Apr 20, 2026 BCLS Fund IV Investments GP, LLC 10% owner Derivative conversion +16,875,000 — —
Apr 20, 2026 Andrew T. Kaplan Director, 10% owner Derivative conversion +17,857,143 — —
Apr 20, 2026 RTW INVESTMENTS, LP 10% owner Open-market purchase +500,000 $16.00 $8,000,000
Apr 20, 2026 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner Derivative conversion +2,034,133 — —
Apr 20, 2026 BCPE Perseus Investor, LP 10% owner Open-market purchase +8,398,438 $16.00 $134,375,008
Apr 20, 2026 Adam Koppel Director, 10% owner Derivative conversion +4,145,768 — —
Apr 20, 2026 BCLS Fund IV Investments GP, LLC 10% owner Derivative conversion +4,145,768 — —
Apr 20, 2026 Andrew T. Kaplan Director, 10% owner Open-market purchase +8,398,438 $16.00 $134,375,008
Apr 20, 2026 Adam Koppel Director, 10% owner Open-market purchase +1,562,500 $16.00 $25,000,000
Apr 20, 2026 BCLS Fund IV Investments GP, LLC 10% owner Open-market purchase +1,562,500 $16.00 $25,000,000

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.